1 The most common serious adverse
events were anaemia (eight [4%]), upper gastrointestinal haem
2 Incident coronary
events were ascertained over a median follow-up of 9.3 years.
3 Safety
events were assessed at 3 months.
4 Adverse
events were attributable to 23 (5%) deaths in the docetaxel,
5 Adverse
events were common with medications but not with CBT and were
6 TE
events were comparable after enoxaparin initiation (14% PAG v
7 erved numbers of first hospitalizations for cerebrovascular
events were compared with that expected from the general popu
8 Adverse
events were defined as fatal or nonfatal aortic rupture, rapi
9 roup, the most frequently reported grade 3 or worse adverse
events were diarrhoea (103 [21%] of 488 patients) followed by
10 ssociations between baseline variables and incident cardiac
events were estimated with hazard ratios and 95% confidence i
11 AG arm led to a clinical hold; thereafter, patients with TE
events were excluded and enoxaparin prophylaxis was initiated
12 Serious adverse
events were experienced by 35 (18%) patients in the olaparib
13 Treatment-related adverse
events were generally grade 1 or 2 in severity.
14 Adverse
events were generally mild (</= grade 2), with diarrhea (44%)
15 gned (intention-to-treat population, n=570) 24 week relapse
events were greater for XR-NTX (185 [65%] of 283) than for BU
16 Thirteen serious adverse
events were identified among recipients of HRV, but none were
17 The most common adverse
events were infective pulmonary exacerbations, cough, increas
18 The most common isatuximab-related adverse
events were infusion-associated reactions (IARs) (56%), which
19 his occurred as bans on participation by women in endurance
events were lifted.
20 Data on adverse
events were limited, but suggested an increased risk of renal
21 These
events were linked to a decrease in the macrophage capacity f
22 All the adverse
events were mild or moderate in severity.
23 The hybridisation
events were monitored by electrochemical impedance spectrosco
24 Adverse
events were more frequent with clindamycin (58 of 265 [21.9%]
25 Adverse
events were more frequent with tofacitinib than with placebo.
26 rFIXFc; in the 30 enrolled patients the most common adverse
events were nasopharyngitis (n=7; 23%) and fall (n=6; 20%); f
27 In subjects without airflow obstruction, acute respiratory
events were not associated with additional FEV1 decline.
28 In this small study, no safety
events were noted, but no safety conclusions can be drawn.
29 Deaths due to adverse
events were observed in 27 (12%) patients in the pacritinib g
30 Fewer grade 3 and 4 treatment-related adverse
events were observed in patients on nivolumab (14% v 34%).
31 ne transporter, in which multiple spontaneous Na(+) release
events were observed.
32 Adverse
events were rarely reported.
33 No severe adverse
events were recorded.
34 Unfolding
events were registered in the phase diagram of glutenins up t
35 Adverse
events were reported as expected and were similar between the
36 Grade 3 to 4 treatment-related adverse
events were reported in 38.3% and 61.7% of the patients in th
37 Serious adverse
events were reported in 56 (58%) eltrombopag-treated patients
38 Serious adverse
events were reported in 64 (22%) of 288 patients in the bupar
39 ) of 44 patients had grade 3 adverse events, but no grade 4
events were reported.
40 No severe vaccine-related adverse
events were reported.
41 Most adverse
events were respiratory, and in some patients it led to drug
42 Neurological and neurocognitive
events were similar among the 3 groups.
43 Adverse
events were similar between the subgroups.
44 The rates of renal adverse
events were similar in the liraglutide group and the placebo
45 The most common adverse
events were skin reactions occurring in 49 (48%) of 103 CGM p
46 Patient characteristics and adverse
events were studied and compared between patients with and wi
47 The binding
events were studied by monitoring cyclic voltammetry signals
48 Features of specific repositioning
events were then tested by fluorescence in situ hybridization
49 0 mg/m(2) The most common grade 3 to 4 drug-related adverse
events were thrombocytopenia (47%), neutropenia (32%), anemia
50 The most frequently observed grade 3 and 4 adverse
events were transaminase increases (40% alanine aminotransfer